Clinical Trials Directory

Trials / Unknown

UnknownNCT02317159

Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia

Status
Unknown
Phase
Phase 4
Study type
Interventional
Enrollment
90 (estimated)
Sponsor
Cttq · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This is a efficacy and safety study of imatinib Mesylate Capsule as First line treatment in patients with chronic phase of Chronic Myeloid Leukemia.

Conditions

Interventions

TypeNameDescription
DRUGImatinib400mg imatinib qd PO

Timeline

Start date
2015-02-01
Primary completion
2017-06-01
Completion
2017-07-01
First posted
2014-12-15
Last updated
2014-12-15

Source: ClinicalTrials.gov record NCT02317159. Inclusion in this directory is not an endorsement.

Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid (NCT02317159) · Clinical Trials Directory